Amplifiers

Minute Molecular Awarded $21.3 Million From NIH RADx Initiative To Accelerate Manufacturing Of DASH 15 minute PCR COVID-19 Test

Retrieved on: 
Thursday, April 22, 2021
Biotechnology, FDA, Health, Other Health, Other Education, Continuing, Other Science, University, Research, Medical devices, Infectious diseases, Education, General Health, Science, Branches of biology, Biology, Biotechnology, Life sciences, Medical tests, Molecular biology, Amplifiers, Laboratory techniques, COVID-19 testing, Molecular diagnostics, Polymerase chain reaction, Rapid antigen test, Minute Molecular, Northwestern University Center for Innovation in Global Health Technologies (CIGHT):, MINUTE MOLECULAR, NORTHWESTERN UNIVERSITY CENTER FOR INNOVATION IN GLOBAL HEALTH TECHNOLOGIES (CIGHT):

View the full release here: https://www.businesswire.com/news/home/20210422006171/en/\nA nasal swab being processed by DASH at a sample collection site.

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210422006171/en/\nA nasal swab being processed by DASH at a sample collection site.
  • (Photo: Business Wire)\n\xe2\x80\x9cWe are pleased to receive support from NIH through the RADx initiative to scale our innovative technology during this critical time of need,\xe2\x80\x9d said Dr. David Kelso, co-founder, President, and CEO of Minute Molecular Diagnostics.
  • \xe2\x80\x9cThe simplicity of the DASH test allows PCR testing to go where antigen tests go now.\xe2\x80\x9d\nThe DASH system is the result of collaboration between Northwestern University\xe2\x80\x99s Center for Innovation in Global Health Technologies (CIGHT) and Minute Molecular.
  • Minute Molecular acknowledges the essential assistance of the NIH in making Point-of-Care PCR COVID-19 testing an effective reality.\nAbout Minute Molecular: Minute Molecular was founded in 2017 as a spin out of the Northwestern University Center for Innovation in Global Health Technology (CIGHT).

Applied DNA Provides Preliminary Estimated Fiscal Second Quarter 2021 Revenue Range and Business Update

Retrieved on: 
Wednesday, April 21, 2021
Medical Supplies, Health, Infectious diseases, Genetics, Clinical trials, Biotechnology, Laboratory techniques, Molecular biology, Natural sciences, Biotechnology, Amplifiers, Science and technology, Life sciences, Hoffmann-La Roche, Polymerase chain reaction

b'Applied DNA Sciences, Inc. (NASDAQ: APDN) (\xe2\x80\x9cApplied DNA\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today provided a preliminary estimated revenue range for the fiscal second quarter ended March 31, 2021 and a business update.

Key Points: 
  • b'Applied DNA Sciences, Inc. (NASDAQ: APDN) (\xe2\x80\x9cApplied DNA\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today provided a preliminary estimated revenue range for the fiscal second quarter ended March 31, 2021 and a business update.
  • The Company expects revenues for its fiscal second quarter to be in the range of $2.5 million to $2.7 million.
  • This compares to revenues of $1.6 million in the fiscal first quarter of 2021 and $552 thousand in the fiscal second quarter of 2020.
  • The Company expects to issue full financial results for the second fiscal quarter of 2021 in mid-May 2021.\nDr.

QIAGEN Launches artus Prep&Amp as CE-Marked SARS-CoV-2 Test Offering up to Threefold Increase in Daily Lab Testing Capacity

Retrieved on: 
Tuesday, April 20, 2021
Research, Medical Supplies, Infectious diseases, Chemicals, Plastics, Manufacturing, Biotechnology, Health, Other Science, Science, Articles, Life sciences, Biology, Molecular biology, Biotechnology, Laboratory techniques, Medical software, Qiagen, Amplifiers, Polymerase chain reaction, COVID-19

\xe2\x80\x9cWe continue to see the need for a large volume of PCR tests as COVID-19 cases continue around the world \xe2\x80\x93 and our novel technology will enable clinical labs to drastically increase testing capacity with existing infrastructure.

Key Points: 
  • \xe2\x80\x9cWe continue to see the need for a large volume of PCR tests as COVID-19 cases continue around the world \xe2\x80\x93 and our novel technology will enable clinical labs to drastically increase testing capacity with existing infrastructure.
  • It is also an exciting and versatile technology with additional potential applications.\xe2\x80\x9d\nQIAGEN has one of the most comprehensive SARS-CoV-2 research and testing portfolios.
  • Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials.
  • As of December 31, 2020, QIAGEN employed approximately 5,600 people in over 35 locations worldwide.

Mirimus, Inc. Partners with St. John's Athletics to Enable COVID-19 Surveillance Testing of Student Athletes Using Pioneering SalivaClear Pooled Testing Platform

Retrieved on: 
Tuesday, April 20, 2021
Branches of biology, Articles, Life sciences, Biotechnology, Medical tests, Molecular biology, Laboratory techniques, COVID-19 testing, Amplifiers, Molecular diagnostics, COVID-19, Polymerase chain reaction

The SalivaClear platform consists of three key elements saliva-based sampling, pooled testing and gold-standard PCR molecular diagnostics that, when combined, enable frequent, high-quality, high-throughput, low-cost detection of SARS-CoV-2, the virus that causes COVID-19.\nSt.

Key Points: 
  • The SalivaClear platform consists of three key elements saliva-based sampling, pooled testing and gold-standard PCR molecular diagnostics that, when combined, enable frequent, high-quality, high-throughput, low-cost detection of SARS-CoV-2, the virus that causes COVID-19.\nSt.
  • Since St. John\'s program with Mirimus began, more than 8,000 saliva-based tests comprising more than 330 pools have been performed.
  • The pooled test results are typically reported to St. John\'s within 24 hours of sample receipt at the laboratory.
  • "\nSalivaClear, developed by Mirimus, Inc., is a pioneering COVID-19 testing platform that combines saliva-based sampling, pooled testing and PCR diagnostics to enable high-quality, high-throughput, low-cost detection of SARS-CoV-2.

Biocept Provides Update on COVID-19 Testing with More than 350,000 Samples Received to Date

Retrieved on: 
Wednesday, April 14, 2021
Oncology, Medical Supplies, Medical devices, Health, Infectious diseases, Biotechnology, Articles, Molecular biology, Laboratory techniques, Natural sciences, Life sciences, Biotechnology, Polymerase chain reaction, Amplifiers, Reverse transcription polymerase chain reaction, Forward-looking statement, COVID-19

(Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that since the Company began offering SARS-CoV-2 testing services in June 2020, it has now received more than 350,000 samples for testing.

Key Points: 
  • (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that since the Company began offering SARS-CoV-2 testing services in June 2020, it has now received more than 350,000 samples for testing.
  • Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
  • The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release.
  • We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.

Eurofins Covid Testing Services Ltd (ECTS) Supports Reopening UK Travel by Making PCR Testing Affordable for All

Retrieved on: 
Tuesday, April 13, 2021
Health, Infectious diseases, Other Travel, Other Health, General Health, Travel, Articles, Branches of biology, Biology, COVID-19 testing, Amplifiers, Laboratory techniques, Molecular biology, Eurofins Scientific, Polymerase chain reaction

b'Eurofins Covid Testing Services Ltd (ECTS) recognises the importance of testing in the fight against COVID-19.

Key Points: 
  • b'Eurofins Covid Testing Services Ltd (ECTS) recognises the importance of testing in the fight against COVID-19.
  • Only the PCR test can provide the accuracy, reliability and variant tracking required to ensure the continued safety of everyone in the UK and whilst travelling.\nECTS wants to support the airline, travel and tourism industries and facilitate travel for all by removing the barrier of expensive testing.
  • ECTS has therefore recently made significant investments in technology and automation to be able to drastically reduce the price of test-at-home PCR kits to just \xc2\xa344.90, providing the UK\xe2\x80\x99s lowest cost option for both Test-To-Depart and Test-To-Release.
  • With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins\xe2\x80\x99 companies offer a portfolio of over 200,000 analytical methods.\nEurofins Shares are listed on Euronext Paris Stock Exchange.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210413005843/en/\n'

GT Molecular launches highly sensitive PCR-based tests for UK, South African, and Brazilian/Japanese Variants of Concern

Retrieved on: 
Wednesday, April 14, 2021
Molecular biology, Laboratory techniques, Natural sciences, Branches of biology, Biology, Polymerase chain reaction, Biotechnology, Amplifiers, Real-time polymerase chain reaction, Digital polymerase chain reaction, Variants of SARS-CoV-2, Severe acute respiratory syndrome coronavirus

NationwideFee-for-servicetesting of wastewater samples for UK, South African, and Brazilian/Japanese Variants of SARS-CoV-2\n2.

Key Points: 
  • NationwideFee-for-servicetesting of wastewater samples for UK, South African, and Brazilian/Japanese Variants of SARS-CoV-2\n2.
  • "As mutations and variants gained traction, GT Molecular created new tools producing highly accurate, well-reported and timely variant data to our City, which has been shared throughout decision-makers in Florida.
  • GT Molecular\'s data has been validated by our state\'s lab as accurate and reliable.
  • says Dr. Lauren Stadler, Assistant Professor at Rice University.\nGT Molecular is a leader in providing highly customizable, ultrasensitive digital PCR and qPCR tests.

FDA Authorizes New High-Throughput, Automated System for Leading COVID-19 Test

Retrieved on: 
Monday, April 12, 2021
Science and technology, Molecular biology, Articles, Laboratory techniques, Natural sciences, Biotechnology, Polymerase chain reaction, Amplifiers, Tecan, Thermo Fisher Scientific, Real-time polymerase chain reaction

"For population-wide testing programs, lab-based PCR is the best fitting technology, providing confidence in results, capacity to process thousands of samples a day, and consistent, reliable turnaround times.

Key Points: 
  • "For population-wide testing programs, lab-based PCR is the best fitting technology, providing confidence in results, capacity to process thousands of samples a day, and consistent, reliable turnaround times.
  • The Amplitude Solution can help support a systematic testing strategy by enabling labs to quickly scale their testing and begin processing high-volume samples, even with limited personnel.
  • "\nThe Amplitude Solution is a molecular diagnostic testing system that helps clinical labs expand testing capacity by combining Thermo Fisher\'s extraction and real-time PCR instruments with liquid handling products from Tecan Group.
  • 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.\nThermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion.

Oligonucleotide Synthesis Market worth $14.1 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, April 9, 2021
Branches of biology, Molecular biology, Biology, Life sciences, Biotechnology, Laboratory techniques, DNA replication, Amplifiers, Polymerase chain reaction, Primer, Oligonucleotide, Biosearch Technologies

Based on end users, the oligonucleotide synthesis market is categorized into hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, contract manufacturing organizations (CMOs) & contract research organizations (CROs), and academic & government institutes.

Key Points: 
  • Based on end users, the oligonucleotide synthesis market is categorized into hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, contract manufacturing organizations (CMOs) & contract research organizations (CROs), and academic & government institutes.
  • The PCR sub segment accounted for the largest share of the research application segment in the oligonucleotide synthesis market in 2020.
  • These PCR applications utilize sequence-specific primers, thus boosting the market for oligos (which are used as probes and primers) in the PCR market.
  • The Asia Pacific region is the fastest growing region of the oligonucleotide synthesis market in 2020.

Oligonucleotide Synthesis Market worth $14.1 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, April 9, 2021
Branches of biology, Molecular biology, Biology, Life sciences, Biotechnology, Laboratory techniques, DNA replication, Amplifiers, Polymerase chain reaction, Primer, Oligonucleotide, Biosearch Technologies

Based on end users, the oligonucleotide synthesis market is categorized into hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, contract manufacturing organizations (CMOs) & contract research organizations (CROs), and academic & government institutes.

Key Points: 
  • Based on end users, the oligonucleotide synthesis market is categorized into hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, contract manufacturing organizations (CMOs) & contract research organizations (CROs), and academic & government institutes.
  • The PCR sub segment accounted for the largest share of the research application segment in the oligonucleotide synthesis market in 2020.
  • These PCR applications utilize sequence-specific primers, thus boosting the market for oligos (which are used as probes and primers) in the PCR market.
  • The Asia Pacific region is the fastest growing region of the oligonucleotide synthesis market in 2020.